Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

NCT06112340 is registered in ClinicalTrials.gov with Sling Therapeutics, Inc. as lead sponsor.

NCT NCT06112340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06112340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Lead sponsor
Sling Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
October 11, 2023
Completion date
June 30, 2026
Enrollment
75 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

endocrine system diseases, exophthalmos, eye diseases, graves ophthalmopathy, graves orbitopathy, hashimoto, igf1r, orbital diseases, proptosis, thyroid associated ophthalmopathy, thyroid diseases, thyroid eye disease